UCB’s Fintepla has been approved to treat seizures associated with two epilepsy disorders and now has posted data that could ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Merck KGaA executive Renee Connolly and Gen Z recording artist Lola Young joined Havas Health and Creative Networks CEO Donna ...

The medtech this week launched a podcast called “Decoded,” in which founder and CEO Jurgi Camblong, Ph.D., will host expert ...

Two and a half years into his tenure as Teva’s CEO, Richard Francis is breaking down the strategy that’s powered the company ...

A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...

Restricted availability under an FDA-mandated drug safety program has limited the reach of CAR-T cell therapies for certain blood cancers—until now. | The FDA has removed the REMS requirements for ...

Ocular Therapeutix is making sure its corporate vision is 20/20 as it looks forward to phase 3 data on its eye disease drug candidate Axpaxli. | Ocular Therapeutix is making sure its corporate vision ...

After over a decade spent building Incyte up into a competitive commercial drugmaker, the company’s longtime CEO Hervé ...

The CDC’s Advisory Committee on Immunization Practices (ACIP) has blessed Merck’s new respiratory syncytial virus (RSV) shot ...

For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...